Penserra Capital Management LLC Buys Shares of 12,130 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Penserra Capital Management LLC purchased a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 12,130 shares of the medical equipment provider's stock, valued at approximately $1,331,000.

Several other large investors have also modified their holdings of LNTH. GAMMA Investing LLC boosted its stake in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider's stock worth $26,000 after acquiring an additional 208 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after acquiring an additional 92 shares in the last quarter. Nkcfo LLC bought a new stake in shares of Lantheus during the 2nd quarter worth $47,000. UMB Bank n.a. boosted its stake in shares of Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in shares of Lantheus during the 3rd quarter worth $51,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Down 1.6 %

LNTH opened at $89.53 on Wednesday. The stock has a market cap of $6.23 billion, a price-to-earnings ratio of 14.90 and a beta of 0.51. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a fifty day moving average price of $102.80 and a 200 day moving average price of $97.04.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research report on Thursday, November 7th. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. Finally, Truist Financial reaffirmed a "buy" rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.50.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.